The use of chromatography to manufacture purer and safer plasma products.
Johnston
A
A
CSL Limited, Bioplasma Division, Research and Development Group, 189-209 Camp Road, Broadmeadows, Victoria 3047, Australia. Anna_Johnston@csl.com.au
Adcock
W
W
D000990:Antithrombin III / Q000302:isolation & purification; D001709:Biotechnology; D001798:Blood Proteins / Q000302:isolation & purification; D002845:Chromatography / Q000379:methods*; D005164:Factor IX / Q000302:isolation & purification; D005169:Factor VIII / Q000302:isolation & purification; D005340:Fibrinogen / Q000302:isolation & purification; D006801:Humans; D007136:Immunoglobulins / Q000302:isolation & purification; D010949:Plasma / Q000821:virology; D012449:Safety; D012709:Serum Albumin / Q000302:isolation & purification; D013917:Thrombin / Q000302:isolation & purification; D014780:Viruses / Q000302:isolation & purification; D000515:alpha 1-Antitrypsin / Q000302:isolation & purification
D001798:Blood Proteins; D007136:Immunoglobulins; D012709:Serum Albumin; D000515:alpha 1-Antitrypsin; D000990:Antithrombin III; D005169:Factor VIII; D005164:Factor IX; D005340:Fibrinogen; D013917:Thrombin